Tuesday, Alnylam Pharmaceuticals Inc. (ALNY) announced that it has expanded its multi-regional partnership with Medison Pharma to market RNAi Therapeutics in selected markets in LATAM, or Latin America, and APAC, or Asia-Pacific regions, and additional international markets.This expansion builds on their existing partnership in Central & Eastern Europe and Israel, aiming to enhance patient access globally.

周二，Alnylam Pharmaceuticals Inc.（ALNY）宣布，它已扩大与Medison Pharma的多区域合作伙伴关系，在拉丁美洲、拉丁美洲、亚太地区或其他国际市场的选定市场销售RNAi疗法。这一扩张建立在他们在中东欧和以色列现有的合作伙伴关系的基础上，旨在提高全球患者的准入率。

Gil Gurfinkel, CEO of Medison said, 'Our expanding partnership with Alnylam shows just how our one-of-a-kind unified commercial platform, with single alliance management across multiple markets and regions, is of great value to leading biotech companies. This partnership will make Alnylam's therapies available in additional international markets, offering newfound hope for patients suffering from rare diseases.'.

麦迪逊首席执行官吉尔·古芬克尔（GilGurfinkel）表示，“我们与Alnylam不断扩大的合作伙伴关系表明，我们独一无二的统一商业平台，跨多个市场和地区进行单一联盟管理，对领先的生物技术公司具有巨大价值。这种合作关系将使Alnylam的疗法在其他国际市场上可用，为患有罕见疾病的患者提供新的希望。”。

Since first partnering in 2018, Alnylam and Medison have progressively broadened their collaboration to make Alnylam's therapies, including patisiran, vutrisiran, givosiran, and lumasiran, accessible in various international markets. For comments and feedback contact: editorial@rttnews.comBusiness News.

自2018年首次合作以来，Alnylam和Medison逐步扩大了合作范围，使Alnylam的疗法（包括patisiran，vutrisiran，givosiran和lumasiran）在各种国际市场上都可以使用。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股